| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
183,678,000 |
| Market
Cap: |
4.54(B) |
| Last
Volume: |
775,760 |
Avg
Vol: |
773,615 |
| 52
Week Range: |
$23.37 - $33.63 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Delivery |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 581 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Alkermes is a biopharmaceutical company. Co. has a portfolio of marketed products focused on central nervous system disorders such as addiction and schizophrenia and a pipeline of product candidates in the fields of neuroscience and oncology. Co.'s proprietary products include: ARISTADA, which is an extended-release intramuscular injectable suspension approved in the U.S. for the treatment of schizophrenia; ARISTADA INITIO, which is indicated for the initiation of ARISTADA when used for the treatment of schizophrenia in adults; and VIVITROL, which is for the treatment of alcohol dependence and for the prevention of relapse to opioid dependence, following opioid detoxification.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
35,000 |
| Total Buy Value |
$0 |
$0 |
$0 |
$815,735 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
15,666 |
15,666 |
48,238 |
146,962 |
| Total Sell Value |
$454,291 |
$454,291 |
$1,411,373 |
$4,368,837 |
| Total People Sold |
3 |
3 |
3 |
5 |
| Total Sell Transactions |
3 |
3 |
6 |
9 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Pops Richard F |
Director and CEO, Alkermes plc |
• • – |
2021-09-14 |
4 |
D |
$30.60 |
$1,109,770 |
D/D |
(36,267) |
837,455 |
|
- |
|
| Pops Richard F |
Director and CEO, Alkermes plc |
• • – |
2021-09-14 |
4 |
A |
$0.00 |
$0 |
D/D |
81,682 |
873,722 |
|
- |
|
| Alva Emily Peterson |
Director |
• • – |
2021-08-23 |
4 |
B |
$30.22 |
$49,860 |
D/D |
1,650 |
1,650 |
2.39 |
-20% |
|
| Brown Iain Michael |
SVP, Chief Financial Officer |
• • – |
2021-08-19 |
4 |
AS |
$29.99 |
$1,199,600 |
D/D |
(40,000) |
42,980 |
|
-22% |
|
| Brown Iain Michael |
SVP, Chief Financial Officer |
• • – |
2021-08-19 |
4 |
OE |
$16.55 |
$662,000 |
D/D |
40,000 |
82,980 |
|
- |
|
| Mckeon Brian P |
Director |
• • – |
2021-08-02 |
4 |
B |
$26.43 |
$264,269 |
I/I |
10,000 |
10,000 |
2.1 |
-17% |
|
| Gaffin David Joseph |
SVP, CLO, Alkermes, Inc. |
• • – |
2021-07-29 |
4 |
AS |
$26.00 |
$364,000 |
D/D |
(14,000) |
74,597 |
|
-12% |
|
| Gaffin David Joseph |
SVP, CLO, Alkermes, Inc. |
• • – |
2021-07-29 |
4 |
OE |
$16.55 |
$231,700 |
D/D |
14,000 |
88,597 |
|
- |
|
| Anstice David W |
Director |
• • – |
2021-07-01 |
4 |
AS |
$24.58 |
$491,504 |
D/D |
(20,000) |
73,081 |
|
18% |
|
| Anstice David W |
Director |
• • – |
2021-07-01 |
4 |
OE |
$14.60 |
$292,000 |
D/D |
20,000 |
93,081 |
|
- |
|
| Dixon Wendy L |
Director |
• • – |
2021-06-10 |
4 |
AS |
$25.00 |
$625,000 |
D/D |
(25,000) |
41,300 |
|
20% |
|
| Dixon Wendy L |
Director |
• • – |
2021-06-10 |
4 |
OE |
$18.21 |
$455,250 |
D/D |
25,000 |
66,300 |
|
- |
|
| Gaffin David Joseph |
SVP, CLO, Alkermes, Inc. |
• • – |
2021-06-10 |
4 |
AS |
$25.00 |
$337,500 |
D/D |
(13,500) |
74,597 |
|
20% |
|
| Gaffin David Joseph |
SVP, CLO, Alkermes, Inc. |
• • – |
2021-06-10 |
4 |
OE |
$16.55 |
$223,425 |
D/D |
13,500 |
88,097 |
|
- |
|
| Hopkinson Craig C. |
EVP R&D, Chief Medical Officer |
• • – |
2021-06-09 |
4 |
AS |
$24.60 |
$21,697 |
D/D |
(882) |
0 |
|
28% |
|
| Gaffin David Joseph |
SVP, CLO, Alkermes, Inc. |
• • – |
2021-06-07 |
4 |
AS |
$24.00 |
$324,000 |
D/D |
(13,500) |
74,597 |
|
34% |
|
| Gaffin David Joseph |
SVP, CLO, Alkermes, Inc. |
• • – |
2021-06-07 |
4 |
OE |
$16.55 |
$223,425 |
D/D |
13,500 |
88,097 |
|
- |
|
| Anstice David W |
Director |
• • – |
2021-06-07 |
4 |
AS |
$24.00 |
$120,000 |
D/D |
(5,000) |
73,081 |
|
34% |
|
| Anstice David W |
Director |
• • – |
2021-06-07 |
4 |
OE |
$14.60 |
$73,000 |
D/D |
5,000 |
78,081 |
|
- |
|
| Hopkinson Craig C. |
EVP R&D, Chief Medical Officer |
• • – |
2021-06-07 |
4 |
D |
$23.50 |
$8,648 |
D/D |
(368) |
882 |
|
- |
|
| Hopkinson Craig C. |
EVP R&D, Chief Medical Officer |
• • – |
2021-06-07 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,250 |
1,250 |
|
- |
|
| Nichols Christian Todd |
SVP, Chief Commercial Officer |
• • – |
2021-06-05 |
4 |
D |
$23.08 |
$23,749 |
D/D |
(1,029) |
7,474 |
|
- |
|
| Nichols Christian Todd |
SVP, Chief Commercial Officer |
• • – |
2021-06-05 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,500 |
8,503 |
|
- |
|
| Gaynor Richard |
Director |
• • – |
2021-05-20 |
4 |
D |
$21.92 |
$30,776 |
D/D |
(1,404) |
4,700 |
|
- |
|
| Gaynor Richard |
Director |
• • – |
2021-05-20 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,104 |
6,104 |
|
- |
|
1496 Records found
|
|
Page 13 of 60 |
|
|
0.66 (2.74%) 
